**Specifications Table**TableSubject area*Biology*More specific subject area*Toxicology, Popliteal Lymph Node Assay, Metal-on-Metal Hip Implants, Histology, Metal Sensitization, Immune Stimulation*Type of data*Tables, figures*How data was acquired*Observation, Microscope and Hemocytometer, Scanning Electron Microscope (Hitachi S5500), Electron Dispersive Spectroscope, Flow Cytometer (BD FacsScan)*Data format*Analyzed*Experimental factors*BALB/c mice were given a single footpad injection of Cr*~*2*~*O*~*3*~*particles, metal salts (CoCl*~*2*~*, CrCl*~*3*~*, and NiCl*~*2*~*), Cr*~*2*~*O*~*3*~*particles plus metal salts, or controls. Four to 11 days later the immune response in the popliteal lymph node (PLN) was assessed.*Experimental features*Four to 11 days following the footpad injection of Cr*~*2*~*O*~*3*~*particles, metal salts (CoCl*~*2*~*, CrCl*~*3*~*, and NiCl*~*2*~*), Cr*~*2*~*O*~*3*~*particles plus metal salts, or controls, clinical observations and the weight and weight index of the PLN were assessed. Flow cytometry was performed to evaluate the proportion of various immune cells and proliferation of cells in the PLN following treatment with the test articles. Additionally, histology was performed on the PLNs of treated mice.*Data source location*MB Labs, Spinnerstown, PA; Calvert Labs, Scott Township, PA; and RJ Lee Group, Monroeville, PA*Data accessibility*With this article*

**Value of the data**•These data represent the first use of the PLNA to test the immune response in mice treated with Cr~2~O~3~ particles, and will be of value to researchers studying metal sensitization.•Histological parameters, including development of germinal centers and hyperplasia of lymphocytes in the cortex, are presented for mice treated with the test articles. These data will be of value in trying to understand the type of immune response observed following treatment with metal particles and ions and to researchers evaluating PLN histology following treatment with metals or other agents.•Flow cytometry was performed, evaluating the response of various types of immune cells, including B220^+^, CD3^+^, CD4^+^, CD8^+^, I-AD^+^ and CD69^+^ cells. These data will be of value in trying to fully characterize the type of immune response observed following treatment with metal particles and ions and to researchers evaluating changes in the percentage of immune cells in the PLN following treatment with metals or other agents.•PLN weight, flow cytometry and histology endpoints were all evaluated in the same treatment groups, allowing comparison across multiple endpoints to better assess the immune response. These data will be of value to researchers evaluating the immune response following treatment with metals or other agents.

1. Data {#s0005}
=======

This data in brief article contains data on the induced immune response in the popliteal lymph node (PLN) of mice treated with Cr~2~O~3~ particles and/or metal salts from two experiments. From the first experiment, the following data are presented: compositional analysis of TiO~2~ particles ([Supplementary Fig. 1](#s0070){ref-type="sec"}); evaluation of localized inflammation ([Supplementary Table 1](#s0070){ref-type="sec"}) and discoloration ([Supplementary Table 2](#s0070){ref-type="sec"}) in the footpad; mean footpad swelling ([Supplementary Fig. 2](#s0070){ref-type="sec"}); mean change in body weight ([Supplementary Fig. 3](#s0070){ref-type="sec"}); mean PLN weight ([Fig. 1](#f0005){ref-type="fig"}); histological evaluation of the PLN ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}); and representative flow cytometry plots for the percentage of cells positive for CD3 and B220 ([Supplementary Fig. 4, 5](#s0070){ref-type="sec"}), I-A^D^ and CD69 ([Supplementary Fig. 6, 7](#s0070){ref-type="sec"}), CD4 and CD8 ([Supplementary Fig. 8, 9](#s0070){ref-type="sec"}) and BrdU ([Supplementary Fig. 10, 11](#s0070){ref-type="sec"}). From the second experiment, the following data are presented: evaluation of localized inflammation ([Supplementary Table 3](#s0070){ref-type="sec"}) and discoloration ([Supplementary Table 4](#s0070){ref-type="sec"}) in the footpad; mean footpad swelling ([Supplementary Fig. 12](#s0070){ref-type="sec"}); mean change in body weight ([Supplementary Fig. 13](#s0070){ref-type="sec"}); and mean PLN weight ([Fig. 2](#f0010){ref-type="fig"}) and WI ([Fig. 3](#f0015){ref-type="fig"}). Please refer to [@bib1] for related data and interpretations.

2. Experimental design, materials and methods {#s0010}
=============================================

The materials and methods have been described previously [@bib1]. Briefly, the materials and methods were as follows:

2.1. Animals {#s0015}
------------

Nulliparous, experimentally naïve, 6--8 week old female BALB/c mice (Charles River Laboratories) were housed in metal-free, disposable plastic cages. The mice were maintained on a 12-hour light/dark cycle in a temperature-controlled environment, and were acclimatized for at least five days. Distilled water and rodent chow were provided *ad libitum*. All procedures complied with acceptable standards of animal welfare and humane care by the Institutional Animal Care and Use Committee (IACUC) of MB Research (Spinnerstown, PA) and Calvert Labs (Scott Township, PA).

2.2. Chemicals and reagents {#s0020}
---------------------------

The following reagents were purchased from the source listed in [Table 5](#t0025){ref-type="table"}.

2.3. Characterization of metallic particles {#s0025}
-------------------------------------------

The morphology of the TiO~2~ particles was determined using a Hitachi S5500 Ultra-high Resolution Scanning Electron Microscope at an accelerating voltage of 2.0 kV with secondary electron contrast at RJ Lee Group (Monroeville, PA). Composition of the TiO~2~ particles was determined using a Bruker energy dispersive spectroscopy (EDS) detector at an accelerating voltage of 20 kV.

2.4. PLNA {#s0030}
---------

Mice were anesthetized with isoflurane and injected subcutaneously with 50 μL of vehicle or test article into the right hind footpad. The dosing groups are presented in [Table 6](#t0030){ref-type="table"}.

All dilutions were prepared fresh daily and were stirred or vortexed until homogeneous. Dilutions were vortexed prior to dosing each mouse. Treatment doses were based on previous literature and dose-range finding studies [@bib2], [@bib3], [@bib4]. See [@bib1] for a detailed description of the rationale of dose formulations.

2.5. Assessment of footpad swelling and general toxicity {#s0035}
--------------------------------------------------------

The injection site of all animals was evaluated for signs of swelling or discoloration, and animals were evaluated for distress or signs of general toxicity approximately four hours after injection and once daily until sacrifice. Right hind footpad swelling was measured at 1, 2 and 4 days post injection in Experiment 1 and from Day 0 to 11 in Experiment 2 using a digital micrometer. Body weights were measured immediately prior to treatment on Day 0 and at sacrifice on Day 4, 7 or 11. Results for footpad swelling and percent of initial body weight are expressed as mean±standard error (SE).

2.6. PLN weight and cell proliferation {#s0040}
--------------------------------------

In Experiment 1, five hours before sacrifice on Day 4, mice were administered bromodeoxyuridine (BrdU) dissolved in PBS (3 mg per mouse; intraperitoneal). In Experiment 2, no BrdU was administered. Mice were euthanized with carbon dioxide inhalation, and the ipsilateral PLNs were excised from each mouse. PLNs were placed in PBS, adherent fatty tissue was removed, and PLNs were weighed. Results for ipsilateral PLN weight and weight index (Experiment 2 only) are expressed as mean±standard error (SE).

For each individual PLN, a single cell suspension was made by gentle disaggregation with a disposable pestle, and cells were centrifuged, washed in PBS, and re-suspended in RPMI. In Experiment 1, the isolated LNCs were used for either determination of BrdU incorporation (fixed in 75% EtOH and stored up to one week at −20 °C) or for flow cytometric analyses (stored overnight at 2--8 °C).

To determine BrdU incorporation in Experiment 1, cells were denatured with HCl Triton X Buffer (1 N HCl, 0.5% Triton X) and neutralized by washing with borate buffer (pH 8.5). Nuclei were washed with a staining buffer, incubated with BrdU-FITC (BD Biosciences, clone B44), washed again with staining buffer and resuspended in PBS containing RNase A (Fisher Scientific) and propidium iodide (PI, Sigma-Aldrich). Samples were incubated at room temperature for 30 min, and the percentage of BrdU^+^ nuclei (i.e., percentage of proliferating lymphocytes in the PLN) was determined with a BD FacScan^®^ flow cytometer.

2.7. Flow cytometry {#s0045}
-------------------

In Experiment 1, PLN cells were incubated with either Rat IgG (for B220, CD3, CD4, and CD8) or hamster/mouse IgG (for I-AD and CD69) for ten minutes to block non-specific binding. Approximately 5x10^5^ cells were incubated for 30--45 min on ice with fluorescently-conjugated antibodies in the following pairs: (1) B220-FITC (BD Pharmingen, clone RA3-6B2) and CD3-PE (BD Pharmingen, clone 17A2); (2) CD4-PE (BD Pharmingen, clone RM4-5) and CD8-FITC (BD Pharmingen, clone 53-6.7); or (3) I-AD-FITC (Acris Antibodies, clone 34-5-3S) and CD69-PE (BD Pharmingen, clone H1.2F3). Cells were fixed with 70% ethanol and analyzed by flow cytometry on a BD FacScan^®^ flow cytometer using 15 mW of power at 488 nm excitation wavelength. Data was acquired on BD CellQuest version 3.3 acquisition software, and CellQuest™ and FlowJo were used for data analysis.

2.8. Histology {#s0050}
--------------

For histological evaluation in Experiment 1 (*n*=2 per treatment group), PLNs were fixed in 10% neutral-buffered formalin and embedded in paraffin. Tissues were cut to 5 μm thickness and stained with hematoxylin and eosin (H&E). The pathologist evaluated the following parameters on a 0 to 4 scale: (1) number of primary follicles; (2) number of secondary follicles/germinal centers; (3) maturity of lymphocytes in the cortex; (4) lymphocyte hyperplasia in the paracortex; (5) plasma cells in the medullar cords; (6) necrosis; (7) acute inflammation (edema); and (8) acute inflammation (infiltration of polymorphonuclear cells). The vehicle control groups were used to establish the baseline scores, and the remaining groups were evaluated blinded as to treatment group.

Transparency document. Supplementary material {#s0060}
=============================================

Supplementary material

Appendix A. Supplementary material {#s0070}
==================================

Supplementary material

Nine of the authors (BT, KU, BW, MK, EF, WC, ED, BF and DP) are or were employed by Cardno ChemRisk, a consulting firm that provides scientific advice to the government, corporations, law firms, and various scientific/professional organizations. Cardno ChemRisk has been engaged by DePuy Orthopaedics, Inc., a manufacturer of prosthetic devices, some of which contain cobalt and chromium, to provide general consulting and expert advice on scientific matters, as well as litigation support. This paper was prepared and written exclusively by the authors, without review or comment by DePuy employees or counsel. It is likely that this work will be relied upon in medical research, nutrition research and litigation. One of the authors (DJP) has previously testified on behalf of DePuy in hip implant litigation. It is possible that any or all of the authors may be called upon to serve as expert witnesses on behalf of DePuy. Funding for this study and the preparation of this paper was provided by DePuy. The preparation of the paper, the synthesis of the findings, the conclusions drawn and recommendations made are the exclusive professional work product of the authors and may not necessarily be those of their employer or the financial sponsor of the study.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2016.08.037](http://dx.doi.org/10.1016/j.dib.2016.08.037){#ir0005}.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2016.08.037](http://dx.doi.org/10.1016/j.dib.2016.08.037){#ir0010}.

![PLN weight four days following footpad injection in Experiment 1. Mice either received no injection (sham), or were injected with a vehicle control or test article as indicated. Four days after treatment, mice were sacrificed and the ipsilateral PLN was weighed. Data are presented as the mean+SE.](gr1){#f0005}

![PLN weight 4, 7 and 11 days following footpad injection in Experiment 2. Mice were injected with a vehicle control or test articles as indicated. On D4, D7, and D11, mice were sacrificed and the ipsilateral PLN was weighed. Note that no D4 data were obtained for the 20% DMSO treatment group. Data are presented as the mean±SE.](gr2){#f0010}

![Weight index (WI) following footpad injections in Experiment 2. Mice were injected with vehicle controls or positive controls (A) or test articles (B), as indicated. On D4, D7 and D11, PLN weight was recorded. The WI was calculated as follows: PLN weight ~test\ animal~ / average PLN weight ~appropriate\ vehicle\ control~. Note that no D4 data were obtained for the 20% DMSO treatment group; therefore, WI values were not calculated for AuCl~3~ and K~2~Cr~2~O~7~ at D4. The dashed line indicates a WI value of 2, which is the threshold value for a positive response in the PLNA. Data are presented as the mean±SE.](gr3){#f0015}

###### 

Histology of the PLN of sham control and vehicle controls in Experiment 1. Four days following sham injection or injection of vehicle controls, the indicated histological parameters were evaluated in the PLN.

Table 1

  **Parameter**                                                                      **Treatment Group**                                                                              
  ---------------------------------------------------------------------------------- --------------------- ---- ---- ----- ---- -------------------------------------- ---- ---- ---- ----
  Number of secondary follicles/germinal centers[a](#tbl1fna){ref-type="table-fn"}   −                     −    −    −     −    NA[b](#tbl1fnb){ref-type="table-fn"}   −    −    −    −
  Number of primary follicles[c](#tbl1fnc){ref-type="table-fn"}                      ++++                  ++   ++   +++   ++   NA                                     ++   ++   ++   ++
  Maturity of lymphocytes in cortex[d](#tbl1fnd){ref-type="table-fn"}                \+                    \+   \+   \+    \+   NA                                     \+   \+   \+   \+
  Lymphocyte hyperplasia in paracortex[e](#tbl1fne){ref-type="table-fn"}             ++                    \+   \+   \+    \+   NA                                     \+   \+   −    \+
  Presence of plasma cells in medullary cords[f](#tbl1fnf){ref-type="table-fn"}      −                     −    −    −     −    NA                                     −    −    −    −
  Necrosis[g](#tbl1fng){ref-type="table-fn"}                                         −                     −    −    −     −    NA                                     −    −    −    −
  Acute inflammation: Edema[h](#tbl1fnh){ref-type="table-fn"}                        −                     −    −    −     −    NA                                     −    −    −    −
  Acute inflammation: Polymorphonuclear cells[i](#tbl1fni){ref-type="table-fn"}      −                     −    −    −     −    NA                                     −    −    −    −

: − = absent, + =1--2 follicles, ++ =3--4 follicles.

: NA=tissue not available for analysis.

: − = no cortex present on sample, + =1-2 follicles, ++ =3-4 follicles, +++ =5-6 follicles, ++++ =7-8 follicles.

: + =all small lymphocytes, ++ =\~5% immature lymphocytes, +++ =\~10% immature lymphocytes.

: − = absent, + =minimal size, mature lymphocytes, ++ =medium size, \~5% immature lymphocytes, +++ =large size, \~10% immature lymphocytes, ++++ =extra-large size, \~20% immature lymphocytes.cords filled.

: − = none observed, + =several, ++ =readily apparent, +++ =cords filled.

:−= absent, + =minimal foci.

:− = absent, + = minimal foci.

: − = absent, + = minimal foci.

###### 

Histology of the PLN of positive and negative chemical controls in Experiment 1. Four days following sham injection or injection of vehicle controls, the indicated histological parameters were evaluated in the PLN.

Table 2

  **Parameter**                                                                      **Treatment Group**                                             
  ---------------------------------------------------------------------------------- --------------------- ---- ---- ----- ---- ---- ---- ----- ---- ----
  Number of secondary follicles/germinal centers[a](#tbl2fna){ref-type="table-fn"}   ++                    −    −    −     −    −    \+   \+    −    −
  Number of primary follicles[b](#tbl2fnb){ref-type="table-fn"}                      +++                   ++   \+   +++   ++   ++   \+   +++   ++   ++
  Maturity of lymphocytes in cortex[c](#tbl2fnc){ref-type="table-fn"}                ++                    \+   \+   \+    \+   \+   \+   ++    \+   \+
  Lymphocyte hyperplasia in paracortex[d](#tbl2fnd){ref-type="table-fn"}             \+                    ++   −    ++    −    \+   \+   \+    −    ++
  Presence of plasma cells in medullary cords[e](#tbl2fne){ref-type="table-fn"}      −                     −    −    −     −    −    −    −     −    −
  Necrosis[f](#tbl2fnf){ref-type="table-fn"}                                         −                     −    −    −     −    −    −    −     −    −
  Acute inflammation: Edema[g](#tbl2fng){ref-type="table-fn"}                        −                     −    −    −     −    −    −    −     −    −
  Acute inflammation: Polymorphonuclear cells[h](#tbl2fnh){ref-type="table-fn"}      −                     −    −    −     −    −    −    \+    −    −

: − = absent, + =1--2 follicles, ++ =3--4 follicles.

: − = no cortex present on sample, + =1--2 follicles, ++ =3--4 follicles, +++ =5--6 follicles, ++++ =7--8 follicles.

: + =all small lymphocytes, ++ =\~5% immature lymphocytes, +++ =\~10% immature lymphocytes.

: − = absent, + =minimal size, mature lymphocytes, ++ =medium size, \~5% immature lymphocytes, +++ =large size, \~10% immature lymphocytes, ++++ =extra-large size, \~20% immature lymphocytes.

: − = none observed, + =several, ++ =readily apparent, +++ =cords filled.

:− = absent, + =minimal foci.

: − = absent, + = minimal foci.

: − = absent, + = minimal foci.

###### 

Histology of the PLN of positive and negative metal controls in Experiment 1. Four days following sham injection or injection of vehicle controls, the indicated histological parameters were evaluated in the PLN.

Table 3

  **Parameter**                                                                      **Treatment Group**                                                                                                       
  ---------------------------------------------------------------------------------- --------------------- ---- ---- ----- ----- ---- --- ---- -------------------------------------- ---- ------ ------ ----- ----
  Number of secondary follicles/germinal centers[a](#tbl3fna){ref-type="table-fn"}   −                     −    −    −     −     \+   −   −    NA[b](#tbl3fnb){ref-type="table-fn"}   NA   −      −      −     −
  Number of primary follicles[c](#tbl3fnc){ref-type="table-fn"}                      ++                    ++   ++   ++    +++   ++   −   ++   NA                                     NA   ++     +++    +++   ++
  Maturity of lymphocytes in cortex[d](#tbl3fnd){ref-type="table-fn"}                \+                    \+   \+   +++   \+    ++   −   \+   NA                                     NA   \+     \+     ++    \+
  Lymphocyte hyperplasia in paracortex[e](#tbl3fne){ref-type="table-fn"}             \+                    \+   ++   ++    ++    ++   −   \+   NA                                     NA   ++++   ++++   \+    −
  Presence of plasma cells in medullary cords[f](#tbl3fnf){ref-type="table-fn"}      −                     −    −    −     −     −    −   −    NA                                     NA   −      −      −     −
  Necrosis[g](#tbl3fng){ref-type="table-fn"}                                         −                     −    −    −     −     −    −   −    NA                                     NA   −      −      −     −
  Acute inflammation: Edema[h](#tbl3fnh){ref-type="table-fn"}                        −                     −    −    −     −     −    −   −    NA                                     NA   −      −      −     −
  Acute inflammation: Polymorphonuclear cells[i](#tbl3fni){ref-type="table-fn"}      −                     −    −    −     −     −    −   −    NA                                     NA   −      −      −     −

: − = absent, + =1--2 follicles, ++ =3--4 follicles.

: NA=tissue not available for analysis.

: − = no cortex present on sample, + =1-2 follicles, ++ =3-4 follicles, +++ =5-6 follicles, ++++ =7-8 follicles.

: + =all small lymphocytes, ++ =\~5% immature lymphocytes, +++ =\~10% immature lymphocytes.

: − = absent, + =minimal size, mature lymphocytes, ++ =medium size, \~5% immature lymphocytes, +++ =large size, \~10% immature lymphocytes, ++++ =extra-large size, \~20% immature lymphocytes.

: − = none observed, + =several, ++ =readily apparent, +++ =cords filled.

:− = absent, + =minimal foci.

:− = absent, + = minimal foci.

: = absent, + = minimal foci.

###### 

Histology of the PLN of treatment groups in Experiment 1. Four days following sham injection or injection of vehicle controls, the indicated histological parameters were evaluated in the PLN.

Table 4

  **Parameter**                                                                      **Treatment Group**                                                                                                  
  ---------------------------------------------------------------------------------- --------------------- ----- ------ ----- ---- ----- ------- ---------- ----- ---- ---- ---- ---- ---- ---- ---- ---- -----
  Number of secondary follicles/germinal centers[a](#tbl4fna){ref-type="table-fn"}   ++                    −     −      −     −    \+    **+**   **+**      −     −    \+   −    −    −    −    −    −    ++
  Number of primary follicles[b](#tbl4fnb){ref-type="table-fn"}                      +++                   +++   ++++   +++   ++   +++   **+**   **++++**   +++   ++   ++   \+   ++   \+   ++   ++   ++   +++
  Maturity of lymphocytes in cortex[c](#tbl4fnc){ref-type="table-fn"}                ++                    \+    \+     \+    \+   \+    **+**   **+**      \+    \+   \+   \+   \+   \+   \+   \+   \+   ++
  Lymphocyte hyperplasia in paracortex[d](#tbl4fnd){ref-type="table-fn"}             \+                    ++    ++     ++    \+   ++    −       **++**     \+    −    ++   \+   \+   \+   \+   ++   ++   +++
  Presence of plasma cells in medullary cords[e](#tbl4fne){ref-type="table-fn"}      −                     −     −      −     −    −     −       −          −     −    −    −    −    −    −    −    −    −
  Necrosis[f](#tbl4fnf){ref-type="table-fn"}                                         −                     −     −      −     −    −     −       −          −     −    −    −    −    −    −    −    −    −
  Acute inflammation: Edema[g](#tbl4fng){ref-type="table-fn"}                        −                     −     −      −     −    −     −       −          −     −    −    −    −    −    −    −    −    −
  Acute inflammation: Polymorphonuclear cells[h](#tbl4fnh){ref-type="table-fn"}      −                     −     −      −     −    −     −       −          −     \+   −    −    −    −    −    −    −    −

: − = absent, + =1--2 follicles, ++ =3--4 follicles.

: − = no cortex present on sample, + =1--2 follicles, ++ =3--4 follicles, +++ =5--6 follicles, ++++ =7--8 follicles.

: + =all small lymphocytes, ++ =\~5% immature lymphocytes, +++ =\~10% immature lymphocytes.

: − = absent, + =minimal size, mature lymphocytes, ++ =medium size, \~5% immature lymphocytes, +++ =large size, \~10% immature lymphocytes, ++++ =extra-large size, \~20% immature lymphocytes.

: −= none observed, + =several, ++ =readily apparent, +++ =cords filled.

: − = absent, + =minimal foci.

:− = absent, + = minimal foci.

: − = absent, + = minimal foci.

###### 

Reagents.

Table 5

  **Reagent**                            **CAS \#**   **Source**
  -------------------------------------- ------------ -----------------------------------
  Nickel chloride (NiCl~2~•6H~2~O)       7791-20-0    Sigma-Aldrich
  Chromium chloride (CrCl~3~•6H~2~O)     10060-12-5   Sigma-Aldrich
  Cobalt chloride (CoCl~2~•6H~2~O)       7791-13-1    Sigma-Aldrich
  Chromium oxide particles (Cr~2~O~3~)   1308-38-9    Sigma-Aldrich
  2,4-Dinitrochlorobenzene (DNCB)        97-00-7      Sigma-Aldrich
  2,4-dichloronitrobenzene (DCNB)        611-06-3     Sigma-Aldrich
  Sodium dodecyl sulfate (SDS)           151-21-3     Sigma-Aldrich
  Bromodeoxyuridine (BrdU)               NA           Sigma-Aldrich
  Dimethylsulfoxide (DMSO)               NA           Sigma-Aldrich
  TiO~2~ particles (TiO~2~)              1317-70-0    US Research Nanomaterials, Inc
  Potassium dichromate (K~2~Cr~2~O~7~)   7778-50-9    Fisher Scientific
  Gold chloride (AuCl~3~)                13453-07-1   Acros Organics
  Phosphate buffer saline (PBS)          NA           Hyclone
  Syngeneic vehicle BALB/c mouse serum   NA           Charles River Laboratory
  Flow cytometery antibodies             NA           BD Pharmingen or Acris Antibodies

###### 

Treatment groups and doses used in Experiments 1 and 2.

Table 6

                                                                                                                  Treatment group                              Vehicle     Dose (mg)   Number of mice for cellular endpoints per timepoint   Number of mice for histological endpoints.
  --------------------------------------------------------------------------------------------------------------- -------------------------------------------- ----------- ----------- ----------------------------------------------------- --------------------------------------------
  ***Experiment 1***                                                                                                                                                                                                                         
  Vehicle control                                                                                                 20% DMSO[a](#tbl6fna){ref-type="table-fn"}   \-          \-          16                                                    4
  Serum:PBS[b](#tbl6fnb){ref-type="table-fn"}                                                                     \-                                           \-          16          4                                                     
  Chemical positive control                                                                                       DNCB                                         20% DMSO    0.1250.3    88                                                    22
  Chemical negative control                                                                                       SDS                                          20% DMSO    0.0938      8                                                     2
  DCNB                                                                                                            20% DMSO                                     0.125       8           2                                                     
  0.3                                                                                                             8                                            2                                                                             
  Metal positive control                                                                                          AuCl~3~                                      20% DMSO    0.0156      8                                                     2
  0.0625                                                                                                          8                                            2                                                                             
  0.125                                                                                                           8                                            2                                                                             
  K~2~Cr~2~O~7~                                                                                                   20% DMSO                                     0.00625     8           2                                                     
  0.025                                                                                                           8                                            2                                                                             
  0.050                                                                                                           8                                            2                                                                             
  Particle negative control                                                                                       TiO~2~ particles                             Serum:PBS   0.0210      8                                                     2
  Cr~2~O~3~ particles and/or metal salts[c](#tbl6fnc){ref-type="table-fn"}^,^[d](#tbl6fnd){ref-type="table-fn"}   Cr~2~O~3~ particles                          Serum:PBS   0.0000144   8                                                     2
  0.0101                                                                                                          8                                            2                                                                             
  0.0216                                                                                                          8                                            2                                                                             
  Metal Salts[c](#tbl6fnc){ref-type="table-fn"}                                                                   Serum:PBS                                    0.0000998   8           2                                                     
  0.0699                                                                                                          8                                            2                                                                             
  0.150                                                                                                           8                                            2                                                                             
  Cr~2~O~3~ particles + metal salts[c](#tbl6fnc){ref-type="table-fn"}^,^[d](#tbl6fnd){ref-type="table-fn"}        Serum:PBS                                    0.000114    8           2                                                     
  0.0800                                                                                                          8                                            2                                                                             
  0.171                                                                                                           8                                            2                                                                             
  ***Experiment 2***                                                                                                                                                                                                                         
  Vehicle control                                                                                                 20% DMSO[e](#tbl6fne){ref-type="table-fn"}   \-          \-          5[e](#tbl6fne){ref-type="table-fn"}                   \-
  Serum:PBS                                                                                                       \-                                           \-          10          \-                                                    
  Metal positive control                                                                                          AuCl~3~                                      20% DMSO    0.125       10                                                    \-
  K~2~Cr~2~O~7~                                                                                                   20% DMSO                                     0.025       10          \-                                                    
  Cr~2~O~3~ particles and/or metal salts[c](#tbl6fnc){ref-type="table-fn"}^,^[d](#tbl6fnd){ref-type="table-fn"}   Cr~2~O~3~ particles                          Serum:PBS   0.0216      10                                                    \-
  Cr~2~O~3~ particles + metal salts[c](#tbl6fnc){ref-type="table-fn"}^,^[d](#tbl6fnd){ref-type="table-fn"}        Serum:PBS                                    0.0005      10          \-                                                    
  0.0025                                                                                                          10                                           \-                                                                            
  0.01                                                                                                            10                                           \-                                                                            
  0.04                                                                                                            10                                           \-                                                                            
  0.08                                                                                                            10                                           \-                                                                            

In Experiment 1, there were two 20% DMSO groups (20% DMSO-A, 20% DMSO-B).

In Experiment 1, there were two Serum:PBS groups (Serum:PBS-A, Serum:PBS-B).

The ASTM F1537 standard specifications for wrought CoCr alloys used for surgical implants report that Co, Cr, and Ni content comprise approximately 64%, 28%, and ≤1% of the implant alloy, respectively. The ratio of total individual metal salts was based on these percentages, as discussed in [@bib1].

The ionic form of Co and Ni were administered. For Cr, a ratio of 62:38 particulate form (Cr~2~O~3~) to ionic form (Cr^3+^) was administered as discussed in [@bib1].

For the 20% DMSO group in Experiment 2, no mice were sacrificed at Day 4. At D7 and D11, 5 mice per group were sacrificed.

[^1]: WVC is currently at Medtronic in Jacksonville, FL.
